XML 38 R26.htm IDEA: XBRL DOCUMENT
v3.20.2

Restructuring, Impairment and Related Charges (Tables) | 6 Months Ended
--- | ---
Sep. 30, 2020
Restructuring and Related Activities [Abstract] |
Restructuring, Impairment and Related Costs | Restructuring, impairment, and related charges during the three and six months ended September 30, 2020 consisted of the following:
| Three Months Ended September 30, 2020
(In millions) | U.S. Pharmaceutical |  | International (1) |  | Medical-Surgical Solutions |  | Prescription Technology Solutions |  | Corporate (2) |  | Total
Severance and employee-related costs, net | $ | 6 |  |  | $ | 3 |  |  | $ | 3 |  |  | $ | — |  |  | $ | 4 |  |  | $ | 16 |
Exit and other-related costs (3) | 4 |  |  | 5 |  |  | (1) |  |  | — |  |  | 7 |  |  | 15 |
Asset impairments and accelerated depreciation | — |  |  | 27 |  |  | 1 |  |  | — |  |  | 1 |  |  | 29 |
Total | $ | 10 |  |  | $ | 35 |  |  | $ | 3 |  |  | $ | — |  |  | $ | 12 |  |  | $ | 60 |
(1)Primarily represents costs associated with the operating model and cost optimization efforts described above. (2)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above. (3)Exit and other-related costs primarily consist of project consulting fees.
| Six Months Ended September 30, 2020
(In millions) | U.S. Pharmaceutical |  | International (1) |  | Medical-Surgical Solutions |  | Prescription Technology Solutions |  | Corporate (2) |  | Total
Severance and employee-related costs, net | $ | 7 |  |  | $ | 20 |  |  | $ | 3 |  |  | $ | — |  |  | $ | 24 |  |  | $ | 54 |
Exit and other-related costs (3) | 5 |  |  | 7 |  |  | 2 |  |  | — |  |  | 14 |  |  | 28 |
Asset impairments and accelerated depreciation | — |  |  | 31 |  |  | 1 |  |  | — |  |  | 2 |  |  | 34 |
Total | $ | 12 |  |  | $ | 58 |  |  | $ | 6 |  |  | $ | — |  |  | $ | 40 |  |  | $ | 116 |
(1)Primarily represents costs associated with the operating model and cost optimization efforts described above. (2)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above. (3)Exit and other-related costs primarily consist of project consulting fees. Fiscal 2020 Restructuring, impairment, and related charges during the three and six months ended September 30, 2019 consisted of the following:
| Three Months Ended September 30, 2019
(In millions) | U.S. Pharmaceutical (1) |  | International (2) |  | Medical-Surgical Solutions (3) |  | Prescription Technology Solutions |  | Corporate (4) |  | Total
Severance and employee-related costs, net | $ | 3 |  |  | $ | 5 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 10 |  |  | $ | 19 |
Exit and other-related costs (5) | — |  |  | 4 |  |  | 2 |  |  | — |  |  | 13 |  |  | 19 |
Asset impairments and accelerated depreciation | — |  |  | 3 |  |  | — |  |  | — |  |  | 4 |  |  | 7 |
Total | $ | 3 |  |  | $ | 12 |  |  | $ | 3 |  |  | $ | — |  |  | $ | 27 |  |  | $ | 45 |
(1)Primarily represents costs associated with the relocation of the Company’s corporate headquarters described above. (2)Primarily represents costs associated with the operating model and cost optimization efforts described above. (3)Primarily represents costs associated with a growth initiative which included a reduction in workforce, facility consolidation, and store closures. These initiatives were substantially completed in the year ended March 31, 2020. (4)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above. (5)Exit and other-related costs primarily include project consulting fees.
| Six Months Ended September 30, 2019
(In millions) | U.S. Pharmaceutical (1) |  | International (2) |  | Medical-Surgical Solutions (3) |  | Prescription Technology Solutions |  | Corporate (4) |  | Total
Severance and employee-related costs, net | $ | 2 |  |  | $ | 4 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 16 |  |  | $ | 23 |
Exit and other-related costs (5) | — |  |  | 6 |  |  | 4 |  |  | — |  |  | 23 |  |  | 33 |
Asset impairments and accelerated depreciation | — |  |  | 6 |  |  | 1 |  |  | — |  |  | 5 |  |  | 12 |
Total | $ | 2 |  |  | $ | 16 |  |  | $ | 6 |  |  | $ | — |  |  | $ | 44 |  |  | $ | 68 |
(1)Primarily represents costs associated with the relocation of the Company’s corporate headquarters described above. (2)Primarily represents costs associated with the operating model and cost optimization efforts described above. (3)Primarily represents costs associated with a growth initiative which included a reduction in workforce, facility consolidation, and store closures. These initiatives were substantially completed in the year ended March 31, 2020. (4)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above. (5)Exit and other-related costs primarily include project consulting fees.
Schedule of Restructuring and Asset Impairment Charges | The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2020:
(In millions) | U.S. Pharmaceutical |  | International |  | Medical-Surgical Solutions |  | Prescription Technology Solutions |  | Corporate |  | Total
Balance, March 31, 2020 (1) | $ | 29 |  |  | $ | 66 |  |  | $ | 22 |  |  | $ | 1 |  |  | $ | 39 |  |  | $ | 157 |
Restructuring, impairment, and related charges | 12 |  |  | 58 |  |  | 6 |  |  | — |  |  | 40 |  |  | 116 |
Non-cash charges | — |  |  | (31) |  |  | (1) |  |  | — |  |  | (2) |  |  | (34) |
Cash payments | (15) |  |  | (16) |  |  | (11) |  |  | (1) |  |  | (34) |  |  | (77) |
Other | — |  |  | (1) |  |  | (1) |  |  | — |  |  | (5) |  |  | (7) |
Balance, September 30, 2020 (2) | $ | 26 |  |  | $ | 76 |  |  | $ | 15 |  |  | $ | — |  |  | $ | 38 |  |  | $ | 155 |
(1)As of March 31, 2020, the total reserve balance was $157 million, of which $118 million was recorded in Other accrued liabilities and $39 million was recorded in Other non-current liabilities. (2)As of September 30, 2020, the total reserve balance was $155 million, of which $128 million was recorded in Other accrued liabilities and $27 million was recorded in Other non-current liabilities.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration